Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of @entity13850 for XXXX .

@entity1 @entity13850 @entity1358 @entity1442
OBJECTIVE: This post hoc analysis evaluated treatment-associated quality-adjusted survival (QAS) in @entity1 randomly assigned to @entity13850 or interferon alfa (IFN-alfa), corrected for censoring using inverse probability weighting (IPW), in the @entity1358 ( @entity1358 ) trial. METHODS: Follow-up was divided into 11 time intervals; Kaplan-Meier estimates for not being censored were estimated for each interval. The QAS for each interval was weighted by the inverse probability of not being censored in that interval. Overall treatment-associated QAS was calculated as the sum of the weighted QAS across all follow-up intervals. Differences in mean QAS between @entity13850 and IFN-alfa were evaluated with t-statistics at a two-sided a = 0.05. RESULTS: In total, 416 @entity1 were randomly assigned to @entity13850 (n = 209) or IFN-alfa (n = 207); 400 @entity1 were included in this analysis. Overall weighted mean (standard deviation) QAS during progression-free survival was 111.9 (5.3) days with @entity13850 (n = 204) and 75.7 (6.3) days with IFN-alfa (n = 196). The mean weighted QAS difference of 36.2 days in favor of @entity13850 was significant (p < 0.05). LIMITATIONS: One potential limitation is that the weights developed by the Kaplan-Meier estimates did not allow for covariates to be adjusted among treatment arms. Another possible limitation is that the @entity1358 trial included @entity1 with @entity1358 , and thus it cannot be conclusively determined how our findings would apply to @entity1 with @entity1442 . CONCLUSIONS: @entity1 with poor-prognosis @entity1358 treated with @entity13850 had an incremental gain of 48% (36.2 days) in QAS compared with @entity1 treated with IFN-alfa.
